Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CEO Leslie Trigg sold 14,611 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $0.90, for a total transaction of $13,149.90. Following the completion of the sale, the chief executive officer now owns 880,969 shares in the company, valued at $792,872.10. This represents a 1.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Leslie Trigg also recently made the following trade(s):
- On Tuesday, January 21st, Leslie Trigg sold 65,236 shares of Outset Medical stock. The stock was sold at an average price of $0.80, for a total transaction of $52,188.80.
- On Monday, January 13th, Leslie Trigg sold 33,227 shares of Outset Medical stock. The stock was sold at an average price of $0.81, for a total transaction of $26,913.87.
- On Tuesday, January 7th, Leslie Trigg sold 10,227 shares of Outset Medical stock. The stock was sold at an average price of $1.29, for a total transaction of $13,192.83.
Outset Medical Price Performance
Shares of NASDAQ:OM traded down $0.08 during trading on Friday, reaching $0.88. The company had a trading volume of 696,815 shares, compared to its average volume of 1,430,621. The company has a fifty day moving average of $0.95 and a two-hundred day moving average of $0.83. The stock has a market capitalization of $47.01 million, a P/E ratio of -0.35 and a beta of 2.01. Outset Medical, Inc. has a 12 month low of $0.44 and a 12 month high of $5.22. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12.
Outset Medical (NASDAQ:OM - Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Outset Medical had a negative net margin of 112.57% and a negative return on equity of 175.64%. The business had revenue of $29.47 million for the quarter, compared to the consensus estimate of $28.47 million. Equities research analysts forecast that Outset Medical, Inc. will post -1.99 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada reissued a "sector perform" rating and issued a $3.00 price target on shares of Outset Medical in a report on Tuesday, January 7th.
Check Out Our Latest Stock Report on OM
Hedge Funds Weigh In On Outset Medical
Several institutional investors and hedge funds have recently made changes to their positions in OM. National Bank of Canada FI grew its holdings in shares of Outset Medical by 79.2% during the 3rd quarter. National Bank of Canada FI now owns 52,407 shares of the company's stock valued at $35,000 after purchasing an additional 23,164 shares during the last quarter. Huntington National Bank grew its holdings in Outset Medical by 46.2% in the 3rd quarter. Huntington National Bank now owns 63,306 shares of the company's stock worth $43,000 after acquiring an additional 20,000 shares during the last quarter. Two Sigma Securities LLC grew its holdings in Outset Medical by 190.0% in the 4th quarter. Two Sigma Securities LLC now owns 42,477 shares of the company's stock worth $47,000 after acquiring an additional 27,830 shares during the last quarter. XTX Topco Ltd bought a new stake in Outset Medical in the 4th quarter worth $50,000. Finally, Squarepoint Ops LLC bought a new stake in Outset Medical in the 4th quarter worth $174,000.
Outset Medical Company Profile
(
Get Free Report)
Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Featured Articles
Before you consider Outset Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outset Medical wasn't on the list.
While Outset Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
